Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZA®, for the treatment of Chronic Idiopathic Constipation in adults.

 

Aug 7, 2008
Sucampo Pharmaceuticals to Report Second Quarter 2008 Financial Results on August 14, 2008

Aug 1, 2008
Sucampo Pharmaceuticals Appoints Jan Smilek Acting Chief Financial Officer

Jul 28, 2008
Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients with Liver Cirrhosis